Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05134857 · ClinicalTrials.gov registry record · Phase 2

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

A Phase 2 study of Alcohol Use Disorder (AUD), sponsored by Washington State University.

Recruiting
Registry status
Phase 2
Development phase
205
Enrollment target
1
Study location

NCT05134857: Recruiting Phase 2 study of Alcohol Use Disorder (AUD), sponsored by Washington State University.

NCT05134857 is a Phase 2 study of Alcohol Use Disorder (AUD) that is actively recruiting participants, run by Washington State University. The registered enrollment target is 205 participants, below the 1,817-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05134857, a Phase 2 study of Alcohol Use Disorder (AUD), is actively recruiting participants, sponsored by Washington State University.

RECRUITING
Registry status
Phase 2
Development phase
205 participants
Enrollment target
1
Study location

Study Summary

A phase II randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of zonisamide (ZON) to decrease alcohol use among treatment-seeking adults with an alcohol use disorder (AUD).

Primary Outcome

Consumption of alcohol between participants randomized to ZON+ST vs PLO+ST assessed by participant self report (collected 1x weekly from weeks 1-14 and once at weeks 18, 38, and 54).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Zonisamide

Study Locations (1)

Washington

  • Washington State University - Spokane

Trial Details

FieldValue
Enrollment Target 205 participants
Start Date 2022-01-07
Est. Completion 2026-08-31
Phase Phase 2
Washington State University

64 total trials

What NCT05134857 shows while recruiting

NCT05134857 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 1,817-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05134857 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT05134857 about?

NCT05134857 is a clinical study titled "The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study". A phase II randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of zonisamide (ZON) to decrease alcohol use among treatment-seeking adults with an alcohol use disorder (AUD).

What is the current status of trial NCT05134857?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2022-01-07. Estimated completion is 2026-08-31.

What conditions does trial NCT05134857 study?

This clinical trial studies the following conditions: Alcohol Use Disorder (AUD).

What interventions are being tested in trial NCT05134857?

The interventions under investigation include: Placebo (DRUG), Zonisamide (DRUG).

Who is sponsoring clinical trial NCT05134857?

This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05134857 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder (AUD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05134857's enrollment target sits among peer trials

205 5th of 30 higher than 25 of 30 other Alcohol Use Disorder (AUD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Use Disorder (AUD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03457493 · 205 participants · Phase 1

    The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

  • NCT05283811 · 205 participants · NA

    Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients

  • NCT05304585 · 205 participants · Phase 3

    Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  • NCT05524610 · 205 participants · NA

    Development and Evaluation of a Screening Approach for Sexual Dysfunction in AYA Patients With and Surviving Childhood Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05134857, the US trial registry maintained by the National Library of Medicine. NCT05134857 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.